Literature DB >> 15850906

Influence of number of metastatic lymph nodes on survival of curative resected thoracic esophageal cancer patients and value of radiotherapy: report of 549 cases.

Ze-Fen Xiao1, Zong-Yi Yang, Yan-Jun Miao, Lu-Hua Wang, Wei-Bo Yin, Xian-Zhi Gu, De-Chao Zhang, Ke-Lin Sun, Gui-Yu Chen, Jie He.   

Abstract

PURPOSE: To analyze the significance of the number of metastatic lymph nodes on survival with and without the addition of prophylactic postoperative radiotherapy (RT) after radical resection of thoracic esophageal carcinoma. METHODS AND MATERIALS: A total of 549 thoracic esophageal squamous cell cancer patients who had undergone radical resection were randomized by the envelope method into a surgery-alone group (S, n = 275) and a surgery plus RT group (S+R, n = 274). We performed a retrospective review of all patients according to the extent of metastasis. The patients were classified into three groups: Group 1, 269 patients (49.0%) without lymph node involvement; Group 2, 159 patients (29.0%) with one to two positive nodes; and Group 3, 121 patients (22.0%) with three or more positive lymph nodes.
RESULTS: For the same T stage (T3), the 5-year survival rate for Groups 1, 2, and 3 was 50.6%, 29.3%, and 11.7%, respectively (p = 0.0000). For patients with Stage III, the 5-year survival rate for Groups 1 (T4N0M0), 2 (T3-T4N1M0), and 3 (T3-T4N2M0) was 58.1%, 30.6%, and 14.4%, respectively (p = 0.0092). The 5-year survival rate of the S and S+R groups with positive lymph nodes (Groups 2 and 3) was 17.6% and 34.1% (p = 0.0378). In the positive lymph node groups, the incidence of failure by intrathoracic lymph node metastasis and supraclavicular lymph node metastasis in the S+R group (21.5% and 4.6%, respectively) was lower than in the S group (35.9% and 19.7%, respectively; p <0.012). In the negative lymph node group, the incidence of failure by intrathoracic lymph node metastasis in the S and S+R groups was 27.8% and 13.3%, respectively (p = 0.006). Hematogenous metastasis was the greatest (27.5%) in Group 3 (three or more positive lymph nodes).
CONCLUSION: The number of metastatic lymph nodes is one of the important factors affecting the survival of patients with thoracic esophageal carcinoma. In our study, postoperative RT improved the survival of patients with positive lymph nodes. Additionally, postoperative RT reduced the incidence of intrathoracic recurrence and supraclavicular lymph node metastasis for all patients.

Entities:  

Mesh:

Year:  2005        PMID: 15850906     DOI: 10.1016/j.ijrobp.2004.08.046

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  49 in total

1.  A meta-analysis of lymph node metastasis rate for patients with thoracic oesophageal cancer and its implication in delineation of clinical target volume for radiation therapy.

Authors:  X Ding; J Zhang; B Li; Z Wang; W Huang; T Zhou; Y Wei; H Li
Journal:  Br J Radiol       Date:  2012-06-14       Impact factor: 3.039

2.  The impact of adjuvant radiotherapy on radically resected T3 esophageal squamous cell carcinoma.

Authors:  Shao-bin Chen; Hong-rui Weng; Geng Wang; Di-tian Liu; Hua Li; Hao Zhang; Yu-ping Chen
Journal:  J Cancer Res Clin Oncol       Date:  2015-09-02       Impact factor: 4.553

3.  Detection of lymph node involvement by cytokeratin immunohistochemistry is an independent prognostic factor after curative resection of esophageal cancer.

Authors:  Goran Marjanovic; Markus Schricker; Axel Walch; Axel zur Hausen; Ulrich T Hopt; Andreas Imdahl; Frank Makowiec
Journal:  J Gastrointest Surg       Date:  2010-10-26       Impact factor: 3.452

4.  Recurrence pattern of squamous cell carcinoma in the middle thoracic esophagus after modified Ivor-Lewis esophagectomy.

Authors:  Gang Chen; Zhou Wang; Xiang-Yan Liu; Fan-Ying Liu
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

5.  Recurrence risk model for esophageal cancer after radical surgery.

Authors:  Jincheng Lu; Hua Tao; Dan Song; Cheng Chen
Journal:  Chin J Cancer Res       Date:  2013-10       Impact factor: 5.087

6.  Radiation therapy in the postoperative management of esophageal cancer.

Authors:  Salma K Jabbour; Charles R Thomas
Journal:  J Gastrointest Oncol       Date:  2010-12

7.  The role of postoperative adjuvant chemotherapy for lymph node-positive esophageal squamous cell carcinoma: a propensity score matching analysis.

Authors:  Rong-Qing Qin; Ying-Sheng Wen; Wu-Ping Wang; Ke-Xing Xi; Xiang-Yang Yu; Lan-Jun Zhang
Journal:  Med Oncol       Date:  2016-02-27       Impact factor: 3.064

8.  Characteristics of recurrence after radical esophagectomy with two-field lymph node dissection for thoracic esophageal cancer.

Authors:  Cheng-Lin Li; Fu-Li Zhang; Ya-DI Wang; Chun Han; Guo-Gui Sun; Qing Liu; Yun-Jie Cheng; Shao-Wu Jing; Cong-Rong Yang
Journal:  Oncol Lett       Date:  2012-10-01       Impact factor: 2.967

9.  High-dose chemoradiotherapy followed by surgery versus surgery alone in esophageal cancer: a retrospective cohort study.

Authors:  Meysan Hurmuzlu; Kjell Øvrebø; Odd R Monge; Rune Smaaland; Tore Wentzel-Larsen; Asgaut Viste
Journal:  World J Surg Oncol       Date:  2010-06-01       Impact factor: 2.754

10.  Postoperative extended-volume external-beam radiation therapy in high-risk esophageal cancer patients: a prospective experience.

Authors:  E Yu; P Tai; J Younus; R Malthaner; P Truong; L Stitt; G Rodrigues; R Ash; R Dar; B Yaremko; A Tomiak; B Dingle; M Sanatani; M Vincent; W Kocha; D Fortin; R Inculet
Journal:  Curr Oncol       Date:  2009-08       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.